508 related articles for article (PubMed ID: 17197522)
1. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity.
Bandello F; Lafuma A; Berdeaux G
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):96-103. PubMed ID: 17197522
[TBL] [Abstract][Full Text] [Related]
2. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4.
Dong LM; Childs AL; Mangione CM; Bass EB; Bressler NM; Hawkins BS; Marsh MJ; Miskala P; Jaffee HA; McCaffrey LA;
Am J Ophthalmol; 2004 Jul; 138(1):91-108. PubMed ID: 15234287
[TBL] [Abstract][Full Text] [Related]
3. Vision-related quality of life in patients with bilateral severe age-related macular degeneration.
Cahill MT; Banks AD; Stinnett SS; Toth CA
Ophthalmology; 2005 Jan; 112(1):152-8. PubMed ID: 15629836
[TBL] [Abstract][Full Text] [Related]
4. Vision-related quality of life in patients suffering from age-related macular degeneration.
Berdeaux GH; Nordmann JP; Colin E; Arnould B
Am J Ophthalmol; 2005 Feb; 139(2):271-9. PubMed ID: 15733988
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment.
Slakter JS; Stur M
Surv Ophthalmol; 2005; 50(3):263-73. PubMed ID: 15850815
[TBL] [Abstract][Full Text] [Related]
6. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC; Lade RJ; Adewoyin T; Chong NV
Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
[TBL] [Abstract][Full Text] [Related]
7. Age-related macular degeneration in Onitsha, Nigeria.
Nwosu SN
Niger J Clin Pract; 2011; 14(3):327-31. PubMed ID: 22037079
[TBL] [Abstract][Full Text] [Related]
8. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
[TBL] [Abstract][Full Text] [Related]
9. A comparison of macular translocation with patch graft in neovascular age-related macular degeneration.
Chen FK; Patel PJ; Uppal GS; Rubin GS; Coffey PJ; Aylward GW; Da Cruz L
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1848-55. PubMed ID: 19060287
[TBL] [Abstract][Full Text] [Related]
10. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
11. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
Shah AR; Del Priore LV
Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
[TBL] [Abstract][Full Text] [Related]
12. Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity.
Fletcher DC; Schuchard RA
Optom Vis Sci; 2006 Mar; 83(3):178-89. PubMed ID: 16534460
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and causes of visual impairment and blindness in Icelanders aged 50 years and older: the Reykjavik Eye Study.
Gunnlaugsdottir E; Arnarsson A; Jonasson F
Acta Ophthalmol; 2008 Nov; 86(7):778-85. PubMed ID: 18513265
[TBL] [Abstract][Full Text] [Related]
14. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome).
Abbott EJ; Connor GB; Artes PH; Abadi RV
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1416-23. PubMed ID: 17325191
[TBL] [Abstract][Full Text] [Related]
15. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
Coleman AL; Yu F
Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
[TBL] [Abstract][Full Text] [Related]
16. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.
Wong TY; Chakravarthy U; Klein R; Mitchell P; Zlateva G; Buggage R; Fahrbach K; Probst C; Sledge I
Ophthalmology; 2008 Jan; 115(1):116-26. PubMed ID: 17675159
[TBL] [Abstract][Full Text] [Related]
17. New approaches in the management of choroidal neovascular membrane in age-related macular degeneration.
Verma L; Das T; Binder S; Heriot WJ; Kirchhof B; Venkatesh P; Krebs I; Stolba U; Jahn C; Feichtinger H; Kellner L; Krugluger H; Pawelka I; Frohner U; Kruger A; Li W; Tewari HK
Indian J Ophthalmol; 2000 Dec; 48(4):263-78. PubMed ID: 11340884
[TBL] [Abstract][Full Text] [Related]
18. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration.
Hayashi H; Yamashiro K; Tsujikawa A; Ota M; Otani A; Yoshimura N
Am J Ophthalmol; 2009 Jul; 148(1):83-9.e1. PubMed ID: 19327745
[TBL] [Abstract][Full Text] [Related]
19. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
